( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.08 which represents a slight increase of $0.11 or 1.58% from the prior close of $6.97. The stock opened at $7.02 and ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...